The abstract is read at the publisher; the summary is JClub's.
BVAC-C combined with durvalumab in HPV16/18-positive recurrent or metastatic cervical cancer achieved an objective response rate of 37.9% in 29 evaluable patients.
- Why it matters: Checkpoint inhibitors have limited efficacy after platinum therapy in this setting, so new strategies are needed to improve response and durability in previously treated patients.
- What they did: In a single-arm, open-label phase II trial (NCT04800978), 30 patients received BVAC-C plus durvalumab after progression on platinum-based chemotherapy, and efficacy was assessed by ORR, disease control, and progression-free survival.
- The result: Disease control was 62.1%, with 6-month PFS of 51.7% and median PFS of 8.7 months; longer treatment-free interval (>6 months) was linked to higher ORR (52.9% vs 16.7%, p=0.047), alongside robust PD-L1-independent immune responses.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.